替格瑞洛对行PCI术后患者心肌酶影响及一年随访事件相关性分析  

Effect of Ticagrelor on Myocardial Enzymes in Patients after PCI and Correlation Analysis of One-year Follow-up Events

作　　者：郑耐心[1] 杨国建[1] 李乐 张倩[1] 唐国栋[1] ZHENG Nai-xin;YANG Guo-jian;LI Le;ZHANG Qian;TANG Guo-dong(Beijing Hospital,National Center for Geriatrics,Academy of Geriatrics,Chinese Academy of Medical Sciences,Beijing,100730,China)

机构地区：[1]北京医院国家老年医学中心中国医学科学院老年医学研究院,北京100730

出　　处：《现代生物医学进展》2020年第20期3836-3839,共4页Progress in Modern Biomedicine

基　　金：北京市自然科学基金项目(7171012)。

摘　　要：目的:研究替格瑞洛对行PCI术后患者心肌酶影响及一年随访事件相关性分析。方法:选取2019年5月至2019年12月的133例急性心肌梗死患者。按照随机数表法分为观察组(n=68)和对照组(n=65),两组均采用PCI术治疗,术后对照组采用氯吡格雷治疗,观察组采用替格瑞洛治疗。对比两组治疗效果,心肌血流灌注指标,心肌酶变化,不良反应发生率。结果:治疗后,观察组总有效率显著高于对照组[95.58%(65/68)vs75.38%(49/65)](P<0.05);TIMI3级、TMPG3级及无复流/满血流均显著低于对照组[17.64%(12/68)vs40.00%(26/65),26.47%(18/68)vs46.15%(30/65),7.35%(5/68)vs27.69%(18/65)](P<0.05);LDH、CK、CK-MB均显著低于对照组[(207.38±21.90)U/L vs(253.75±26.37)U/L,(166.38±19.32)U/L vs(389.75±52.03)U/L,(121.58±15.86)U/L vs(162.60±18.75)U/L](P<0.05);一年随访事件发生率显著低于对照组[11.76%(8/68)vs36.92%(24/65)](P<0.05)。结论:替格瑞洛对可有效改善行PCI术后患者血流灌注,保护心肌细胞,改善心肌功能,提高治疗疗效。Objective: To study the effect of ticagrelor on myocardial enzymes in patients after PCI and correlation analysis of one-year follow-up events. Methods: 133 acute myocardial infarction who received therapy from May 2018 to December 2019 in our hospital were selected as research objects. According to random number table, those patients were divided into the observation group(n=68) and the control group(n=65). Both groups were treated with PCI. The control group was treated with clopidogrel. The observation group was treated with ticagrelor. The therapeutic effect, myocardial perfusion index, myocardial enzyme and Incidence of adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of observation group was significantly higher than that of control group[95.58%(65/68) vs 75.38%(49/65)](P<0.05). TIMI 3, tmpg3 and no reflow/full flow were significantly lower than those in the control group [17.64%(12/68) vs 40.00%(26/65), 26.47%(18/68) vs 46.15%(30/65), 7.35%(5/68) vs 27.69%(18/65)](P<0.05). LDH, CK, CK-MB were significantly lower than the control group [(207.38 ±21.90) U/L vs(253.75 ±26.37)U/L,(166.38±19.32) U/L vs(389.75±52.03) U/L,(121.58±15.86)U/L vs(162.60±18.75) U/L](P<0.05). Incidence of one-year follow-up events were significantly lower than those in the control group [11.76%(8/68)vs36.92%(24/65)](P<0.05). Conclusion: Ticagrelor can effectively improve the blood perfusion of patients after PCI, protect myocardial cells, improve myocardial function and improve the therapeutic effect.

关 键 词：替格瑞洛 PCI术 心肌酶 MACE发生率 

分 类 号：R541.4[医药卫生—心血管疾病]